NFE2L2 and ovarian carcinoma: In this study we focus on the NRF2-AKR1C1/2 pathway to further characterize the molecular basis of chemoresistance and propose as therapy option in recurrent ovarian cancer carboplatin in combination with the synthetic progesterone MPA.